Skip to main content

CORRECTION article

Front. Mol. Neurosci., 29 June 2022
Sec. Brain Disease Mechanisms
Volume 15 - 2022 | https://doi.org/10.3389/fnmol.2022.965564

Corrigendum: Type I Interferon Response Is Mediated by NLRX1-cGAS-STING Signaling in Brain Injury

This article is a correction to:

  1. Type I Interferon Response Is Mediated by NLRX1-cGAS-STING Signaling in Brain Injury

    1. Read original article
\nLauren E. FritschLauren E. Fritsch1Jing JuJing Ju2Erwin Kristobal Gudenschwager BassoErwin Kristobal Gudenschwager Basso3Eman SolimanEman Soliman3Swagatika PaulSwagatika Paul4Jiang Chen&#x;Jiang Chen2†Alexandra M. KalossAlexandra M. Kaloss3Elizabeth A. KowalskiElizabeth A. Kowalski3Taylor C. TuhyTaylor C. Tuhy5Rachana Deven SomaiyaRachana Deven Somaiya1Xia WangXia Wang3Irving Coy AllenIrving Coy Allen3Michelle H. Theus, Michelle H. Theus3,5*Alicia M. Pickrell Alicia M. Pickrell5*
  • 1Translational Biology, Medicine, and Health Graduate Program, Virginia Polytechnic Institute and State University, Roanoke, VA, United States
  • 2Molecular and Cellular Biology Graduate Program, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States
  • 3Department of Biomedical Sciences and Pathobiology, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States
  • 4Biomedical and Veterinary Sciences Graduate Program, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States
  • 5School of Neuroscience, Virginia Polytechnic Institute and State University, Blacksburg, VA, United States

A Corrigendum on
Type I Interferon Response Is Mediated by NLRX1-cGAS-STING Signaling in Brain Injury

by Fritsch, L. E., Ju, J., Gudenschwager Basso, E. K., Soliman, E., Paul, S., Chen, J., Kaloss, A. M., Kowalski, E. A., Tuhy, T. C., Somaiya, R. D., Wang, X., Allen, I. C., Theus, M. H., and Pickrell, A. M. (2022). Front. Mol. Neurosci. 15:852243. doi: 10.3389/fnmol.2022.852243

In the published article, there was an error in Table 1 as published. The forward and reverse sequences for the rows “IL-6” and “MCP1” were incorrectly entered as “CTA GCT CAG GCT CGT CAG TTC.” The corrected Table 1 and its caption appear below.

TABLE 1
www.frontiersin.org

Table 1. qPCR primers used in experiments.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: brain injury, inflammation, STING, cGAS, innate immunity

Citation: Fritsch LE, Ju J, Basso EKG, Soliman E, Paul S, Chen J, Kaloss AM, Kowalski EA, Tuhy TC, Somaiya RD, Wang X, Allen IC, Theus MH and Pickrell AM (2022) Corrigendum: Type I Interferon Response Is Mediated by NLRX1-cGAS-STING Signaling in Brain Injury. Front. Mol. Neurosci. 15:965564. doi: 10.3389/fnmol.2022.965564

Received: 09 June 2022; Accepted: 10 June 2022;
Published: 29 June 2022.

Edited and reviewed by: Andrei Surguchov, University of Kansas Medical Center, United States

Copyright © 2022 Fritsch, Ju, Basso, Soliman, Paul, Chen, Kaloss, Kowalski, Tuhy, Somaiya, Wang, Allen, Theus and Pickrell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Alicia M. Pickrell, YWxpY2lhLnBpY2tyZWxsJiN4MDAwNDA7dnQuZWR1; Michelle H. Theus, bXRoZXVzJiN4MDAwNDA7dnQuZWR1

†Present address: Jiang Chen, Sorrento Therapeutics, Inc., San Diego, CA, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.